|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM381972283 |
| 003 |
DE-627 |
| 005 |
20241223232248.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
241223s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202411361
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1640.xml
|
| 035 |
|
|
|a (DE-627)NLM381972283
|
| 035 |
|
|
|a (NLM)39711226
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yan, Wenlu
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Personalized Multi-Epitope Nanovaccine Unlocks B Cell-Mediated Multiple Pathways of Antitumor Immunity
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 23.12.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status Publisher
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a B lymphocytes have emerged as an important immune-regulating target. Inoculation with tumor cell membrane-derived vaccines is a promising strategy to activate B cells, yet their efficiency is limited due to lack of costimulatory molecules. To amplify B cell responses against tumor, herein, a spatiotemporally-synchronized antigen-adjuvant integrated nanovaccine, termed as CM-CpG-aCD40, is constructed by conjugating the immune stimulative CpG oligonucleotide and the anti-CD40 antibody (aCD40) onto the membrane vesicles derived from triple negative breast cancer cells. CM-CpG-aCD40 actively accumulates in lymph nodes and is effectively captured by antigen-presenting cells via the recognition of CD40 by aCD40. Tumor antigens on CM-CpG-aCD40 bind to B cell receptors, providing the first stimulation signal for B cells. Meanwhile, the interaction between CpG/Toll like receptor and aCD40/CD40 provides superposed co-stimulation signals, improving the antibody-secreting and antigen-presenting abilities of B cells. The nanovaccine also stimulates dendritic cells to activate CD8+ T cells, and reprograms tumor associated macrophages. CM-CpG-aCD40 activating humoral, cellular, and innate antitumor immunity achieves a tumor inhibition rate of 89.3%, which is further improved to 95.4% when combined with the anti-programmed death ligand 1 (PD-L1) antibody. CM-CpG-aCD40, as a personalized multi-epitope nanovaccine, paves the way for ushering the era of B cell-based immunotherapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a B lymphocytes
|
| 650 |
|
4 |
|a cellular immunity
|
| 650 |
|
4 |
|a humoral immunity
|
| 650 |
|
4 |
|a nanovaccine
|
| 650 |
|
4 |
|a tumor immunotherapy
|
| 700 |
1 |
|
|a Cao, Ying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Shanshan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Yu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Ting
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yuan, Wenhui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yin, Qi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Yaping
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g (2024) vom: 23. Dez., Seite e2411361
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g year:2024
|g day:23
|g month:12
|g pages:e2411361
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202411361
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2024
|b 23
|c 12
|h e2411361
|